Showing results (51-60 of 1,009) with videos related to
Sort By:
Pageof 101
Cancer Research Communications|March 27, 2023
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)Aaron J Scott, Atrayee Basu Mallick, Efrat Dotan, et al.Cancer Research Communications|March 27, 2023
Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer ImmunotherapyMichael R Paillasse, Michael Esquerré, Florie A Bertrand, et al.Cancer Research Communications|March 27, 2023
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human StudyYasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, et al.Cancer Research Communications|March 27, 2023
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic LeukemiaSandra Dupouy, Ibtissam Marchiq, Thibaud Derippe, et al.Cancer Research Communications|March 27, 2023
Loss of Dok-3 in Non-tumor Cells Induces Malignant Transformation of Benign Epithelial Tumor Cells of the IntestineSumimasa Arimura, Akane Inoue-Yamauchi, Kotoe Katayama, et al.Cancer Research Communications|March 27, 2023
Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell LymphomasXin Gao, Nermin Kady, Chenguang Wang, et al.Cancer Research Communications|March 27, 2023
The Splicing Factor PTBP1 Represses TP63 γ Isoform Production in Squamous Cell CarcinomaWilliam Taylor, Stéphane Deschamps, David Reboutier, et al.Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.Cancer Research Communications|March 27, 2023
Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic AntibodiesJingyu Zhan, Dong Lin, Nathan Watson, et al.Cancer Research Communications|March 27, 2023
Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 ImmunotherapyZhouting Zhu, Rachel Tang, Sarah Huff, et al.Pageof 101